* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Metabolic Disorders - Pipeline Review, H1 2013 Brochure
Survey
Document related concepts
Pharmaceutical marketing wikipedia , lookup
Orphan drug wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Compounding wikipedia , lookup
List of comic book drugs wikipedia , lookup
Pharmacognosy wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug interaction wikipedia , lookup
Theralizumab wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Drug design wikipedia , lookup
Transcript
Brochure More information from http://www.researchandmarkets.com/reports/2508209/ Metabolic Disorders - Pipeline Review, H1 2013 Description: Metabolic Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Metabolic Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metabolic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metabolic Disorders. Metabolic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Metabolic Disorders. - A review of the Metabolic Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metabolic Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Metabolic Disorders. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Metabolic Disorders pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Contents: 2 List of Tables 6 List of Figures 8 Introduction 9 REPORT COVERAGE 9 Metabolic Disorders Overview 10 Therapeutics Development 11 An Overview of Pipeline Products for Metabolic Disorders 11 Metabolic Disorders Therapeutics under Development by Companies 13 Metabolic Disorders Therapeutics under Investigation by Universities/Institutes 19 Late Stage Products 20 Comparative Analysis 20 Mid Clinical Stage Products 21 Comparative Analysis 21 Early Clinical Stage Products 22 Comparative Analysis 22 Discovery and Pre-Clinical Stage Products 23 Comparative Analysis 23 Metabolic Disorders Therapeutics – Products under Development by Companies 24 Metabolic Disorders Therapeutics – Products under Investigation by Universities/Institutes 29 Companies Involved in Metabolic Disorders Therapeutics Development 30 Bristol-Myers Squibb Company 30 Athersys, Inc. 31 Genentech, Inc. 32 Daiichi Sankyo Company, Ltd 33 Merck & Co., Inc. 34 Takeda Pharmaceutical Company Limited 35 Ipsen S.A. 36 Glenmark Pharmaceuticals Ltd. 37 Genfit 38 Arrowhead Research Corporation 39 Ore Pharmaceuticals Inc 40 Corcept Therapeutics Incorporated 41 Alexion Pharmaceuticals, Inc. 42 CSL Limited 43 Regeneron Pharmaceuticals, Inc. 44 Unigene Laboratories, Inc. 45 XOMA Ltd. 46 Torrent Pharmaceuticals Limited 47 Suven Life Sciences Ltd. 48 Debiopharm Group 49 StemCells, Inc. 50 Axxam SpA 51 Camurus AB 52 Sirtris Pharmaceuticals, Inc. 53 Acceleron Pharma, Inc. 54 Helsinn Healthcare S.A. 55 Wellstat Therapeutics Corporation 56 Xenon Pharmaceuticals Inc. 57 Affibody AB 58 Ascent Therapeutics 59 Zafgen Inc. 60 Trevena, Inc. 61 Tranzyme Pharma, Inc. 62 Zealand Pharma A/S 63 Synageva BioPharma Corp. 64 Omeros Corporation 65 Obio Pharmaceutical Holdings Limited. 66 ChemoCentryx, Inc. 67 Vitae Pharmaceuticals, Inc. 68 Limerick BioPharma, Inc. 69 Lipopharma 70 Pharis Biotec GmbH 71 Relypsa, Inc. 72 Regulus Therapeutics Inc. 73 Esperion Therapeutics, Inc. 74 aTyr Pharma, Inc. 75 Heptares Therapeutics Ltd. 76 Envoy Therapeutics, Inc. 77 Zacharon Pharmaceuticals, Inc. 78 Galmed International Ltd. 79 Faron Pharmaceuticals, Ltd. 80 Progenra, Inc. 81 Metabolic Disorders – Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Route of Administration 83 Assessment by Molecule Type 85 Drug Profiles 87 Glucose-Dependent Insulinotropic Peptide - Drug Profile 87 Debio-0930 - Drug Profile 88 G-15750 - Drug Profile 89 TGFTX-1 Program - Drug Profile 90 TGFTX-3 Program - Drug Profile 91 TZP-301 - Drug Profile 92 romazarit - Drug Profile 93 Human Liver Engrafting Cells - Drug Profile 94 Stearoyl-CoA Desaturase-1 Drug Development Program - Drug Profile 96 ETC-1002 - Drug Profile 97 P-2202 - Drug Profile 99 P-7435 - Drug Profile 101 P-1201 - Drug Profile 102 Selective GR-II Receptor Antagonist - Drug Profile 103 Aramchol - Drug Profile 104 Ganglioside Inhibitor Program - Drug Profile 106 RNAi Therapeutics Program - Drug Profile 107 KP-9928 - Drug Profile 108 LIM-0723 - Drug Profile 109 ACE-435 - Drug Profile 110 MTP-131 - Drug Profile 111 GRC-9332 - Drug Profile 113 bezafibrate - Drug Profile 114 citrulline - Drug Profile 115 uridine triacetate - Drug Profile 116 recombinant human Zinc-a2-glycoprotein - Drug Profile 118 T2 Mimetic - Drug Profile 119 SBC-105 - Drug Profile 120 CORT-113083 - Drug Profile 121 RLY-106 - Drug Profile 122 IGF-1 Analogue - Drug Profile 123 LP-205A1 - Drug Profile 124 Ghrelin Receptor Antagonists - Drug Profile 125 Anti microRNA-33a/b - Drug Profile 126 SRT-3025 - Drug Profile 128 Drug For Metabolic Disorders - Drug Profile 130 Drug For Metabolic Disorders - Drug Profile 131 LP-30171 - Drug Profile 132 UX-007 - Drug Profile 133 SUVN-504 - Drug Profile 134 Histamine-3 Antagonist - Drug Profile 135 Drug Acting On Nicotinic Acetylcholine Receptor Alpha-4 Beta-2 For Obesity And Metabolic Disorders - Drug Profile 136 RG-7652 - Drug Profile 137 REGN-1033 - Drug Profile 138 Adipotide - Drug Profile 139 cPMP replacement therapy - Drug Profile 141 GPR120 Agonist - Drug Profile 142 Multiple Preclinical Programs - Drug Profile 143 Novel Peptide for Metabolic Diseases - Drug Profile 144 Second Generation Compounds - Drug Profile 145 CSL-346 - Drug Profile 146 Drug Targeting GPR50 - Drug Profile 147 Cardiometabolic Disease Program - Drug Profile 148 F-652 - Drug Profile 149 CCX-872 - Drug Profile 150 FP-1101/1102 - Drug Profile 151 Resectin Protein Based Drug - Drug Profile 152 Undisclosed Product For Metabolic Diseases - Drug Profile 153 Undisclosed Drug - Drug Profile 154 Program For Diabetes And Obesity - Drug Profile 155 11 Beta HSD-1 Inhibitor Program - Drug Profile 156 Drug Targeting IDOL - Drug Profile 158 Drugs Targeting Acetyl-CoA Carboxylase - Drug Profile 159 Compound-22e - Drug Profile 160 AM-251 - Drug Profile 161 xl-310 - Drug Profile 162 FGF21-Based Biologic - Drug Profile 164 Irisin - Drug Profile 165 Beta-Arrestin Biased GPCR Agonists - Drug Profile 166 Drug For Metabolic And Genetic Disorder - Drug Profile 167 Drug For Metabolic Disorders - Drug Profile 168 Metabolic Disorders Therapeutics – Drug Profile Updates 169 Metabolic Disorders Therapeutics – Discontinued Products 177 Metabolic Disorders Therapeutics - Dormant Products 178 Metabolic Disorders – Product Development Milestones 181 Featured News & Press Releases 181 Appendix 189 Methodology 189 Coverage 189 Secondary Research 189 Primary Research 189 Expert Panel Validation 189 Contact Us 190 Disclaimer 190 List of Tables Number of Products Under Development for Metabolic Disorders, H1 2013 16 Products under Development for Metabolic Disorders – Comparative Analysis, H1 2013 17 Number of Products under Development by Companies, H1 2013 19 Number of Products under Development by Companies, H1 2013 (Contd..1) 20 Number of Products under Development by Companies, H1 2013 (Contd..2) 21 Number of Products under Development by Companies, H1 2013 (Contd..3) 22 Number of Products under Development by Companies, H1 2013 (Contd..4) 23 Number of Products under Investigation by Universities/Institutes, H1 2013 24 Comparative Analysis by Late Stage Development, H1 2013 25 Comparative Analysis by Mid Clinical Stage Development, H1 2013 26 Comparative Analysis by Early Clinical Stage Development, H1 2013 27 Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 28 Products under Development by Companies, H1 2013 29 Products under Development by Companies, H1 2013 (Contd..1) 30 Products under Development by Companies, H1 2013 (Contd..2) 31 Products under Development by Companies, H1 2013 (Contd..3) 32 Products under Development by Companies, H1 2013 (Contd..4) 33 Products under Investigation by Universities/Institutes, H1 2013 34 Bristol-Myers Squibb Company, H1 2013 35 Athersys, Inc., H1 2013 36 Genentech, Inc., H1 2013 37 Daiichi Sankyo Company, Ltd, H1 2013 38 Merck & Co., Inc., H1 2013 39 Takeda Pharmaceutical Company Limited, H1 2013 40 Ipsen S.A., H1 2013 41 Glenmark Pharmaceuticals Ltd., H1 2013 42 Genfit, H1 2013 43 Arrowhead Research Corporation, H1 2013 44 Ore Pharmaceuticals Inc, H1 2013 45 Corcept Therapeutics Incorporated, H1 2013 46 Alexion Pharmaceuticals, Inc., H1 2013 47 CSL Limited, H1 2013 48 Regeneron Pharmaceuticals, Inc., H1 2013 49 Unigene Laboratories, Inc., H1 2013 50 XOMA Ltd., H1 2013 51 Torrent Pharmaceuticals Limited, H1 2013 52 Suven Life Sciences Ltd., H1 2013 53 Debiopharm Group, H1 2013 54 StemCells, Inc., H1 2013 55 Axxam SpA, H1 2013 56 Camurus AB, H1 2013 57 Sirtris Pharmaceuticals, Inc., H1 2013 58 Acceleron Pharma, Inc., H1 2013 59 Helsinn Healthcare S.A., H1 2013 60 Wellstat Therapeutics Corporation, H1 2013 61 Xenon Pharmaceuticals Inc., H1 2013 62 Affibody AB, H1 2013 63 Ascent Therapeutics, H1 2013 64 Zafgen Inc., H1 2013 65 Trevena, Inc., H1 2013 66 Tranzyme Pharma, Inc., H1 2013 67 Zealand Pharma A/S, H1 2013 68 Synageva BioPharma Corp., H1 2013 69 Omeros Corporation, H1 2013 70 Obio Pharmaceutical Holdings Limited., H1 2013 71 ChemoCentryx, Inc., H1 2013 72 Vitae Pharmaceuticals, Inc., H1 2013 73 Limerick BioPharma, Inc., H1 2013 74 Lipopharma, H1 2013 75 Pharis Biotec GmbH, H1 2013 76 Relypsa, Inc., H1 2013 77 Regulus Therapeutics Inc., H1 2013 78 Esperion Therapeutics, Inc., H1 2013 79 aTyr Pharma, Inc., H1 2013 80 Heptares Therapeutics Ltd., H1 2013 81 Envoy Therapeutics, Inc., H1 2013 82 Zacharon Pharmaceuticals, Inc., H1 2013 83 Galmed International Ltd., H1 2013 84 Faron Pharmaceuticals, Ltd., H1 2013 85 Progenra, Inc., H1 2013 86 Assessment by Monotherapy Products, H1 2013 87 Assessment by Stage and Route of Administration, H1 2013 89 Assessment by Stage and Molecule Type, H1 2013 91 Metabolic Disorders Therapeutics – Drug Profile Updates 174 Metabolic Disorders Therapeutics – Discontinued Products 182 Metabolic Disorders Therapeutics – Dormant Products 183 Metabolic Disorders Therapeutics – Dormant Products (Contd..1) 184 Metabolic Disorders Therapeutics – Dormant Products (Contd..2) 185 List of Figures Number of Products under Development for Metabolic Disorders, H1 2013 16 Products under Development for Metabolic Disorders – Comparative Analysis, H1 2013 17 Products under Development by Companies, H1 2013 18 Products under Investigation by Universities/Institutes, H1 2013 24 Late Stage Products, H1 2013 25 Mid Clinical Stage Products, H1 2013 26 Early Clinical Stage Products, H1 2013 27 Discovery and Pre-Clinical Stage Products, H1 2013 28 Assessment by Monotherapy Products, H1 2013 87 Assessment by Route of Administration, H1 2013 88 Assessment by Stage and Route of Administration, H1 2013 89 Assessment by Molecule Type, H1 2013 90 Assessment by Stage and Molecule Type, H1 2013 91 Ordering: Order Online - http://www.researchandmarkets.com/reports/2508209/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Metabolic Disorders - Pipeline Review, H1 2013 Web Address: http://www.researchandmarkets.com/reports/2508209/ Office Code: SCHL3FA7 Product Formats Please select the product formats and quantity you require: Quantity Electronic (PDF) Single User: USD 2000 Electronic (PDF) Site License: USD 4000 Electronic (PDF) Enterprisewide: USD 6000 Contact Information Please enter all the information below in BLOCK CAPITALS Title: First Name: Mr Mrs Dr Miss Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL) Ms Prof Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code ULSBIE2D IBAN number IE78ULSB98533083313083 Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World